Family history of breast cancer as a second primary malignancy in relatives: a nationwide cohort study.
Breast carcinoma
Cancer incidence
Familial clustering
Multiple primary cancer
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
12 Nov 2021
12 Nov 2021
Historique:
received:
21
05
2021
accepted:
14
10
2021
entrez:
13
11
2021
pubmed:
14
11
2021
medline:
19
2
2022
Statut:
epublish
Résumé
With the increasing number of breast cancer (BC) diagnosed as a second primary malignancy after a first primary non-breast cancer (BCa-2), it is unclear about the familial risk of BC among women with a first-degree relative (FDR, parents or siblings) affected by a BCa-2. In this Swedish nationwide cohort study, 5315 women with a FDR affected by BCa-2 and 115,048 women with a FDR affected by BC as the first primary cancer (BCa-1) were followed for the first primary invasive BC diagnosis. Relative risk (RR) of BC was estimated through Poisson regression by using 2,743,777 women without a family history of cancer as reference. The risk was stratified by the diagnostic age of BC in FDR, proband type, the time interval between the first primary cancer and BCa-2 in FDR as well as the site of first primary cancer diagnosed in FDR before BCa-2. We also calculated the cumulative incidence of BC from birth to a specific age for the three groups. The cumulative incidence from birth to age 70 was 10% among women with a family history of BCa-2. The RR of BC with a family history of BCa-2 (RR, 1.68, 95%CI, 1.49 to 1.88) was comparable to that with BCa-1 (1.68, 1.63 to 1.73). The risk was largely consistent irrespective of proband type. The age of onset of BCa-2 in FDR (RR Women with a family history of BCa-2 have a similar overall BC risk as those with a family history of BCa-1. The risk varied according to the site of first primary cancer diagnosed in FDR before BCa-2.
Sections du résumé
BACKGROUND
BACKGROUND
With the increasing number of breast cancer (BC) diagnosed as a second primary malignancy after a first primary non-breast cancer (BCa-2), it is unclear about the familial risk of BC among women with a first-degree relative (FDR, parents or siblings) affected by a BCa-2.
METHODS
METHODS
In this Swedish nationwide cohort study, 5315 women with a FDR affected by BCa-2 and 115,048 women with a FDR affected by BC as the first primary cancer (BCa-1) were followed for the first primary invasive BC diagnosis. Relative risk (RR) of BC was estimated through Poisson regression by using 2,743,777 women without a family history of cancer as reference. The risk was stratified by the diagnostic age of BC in FDR, proband type, the time interval between the first primary cancer and BCa-2 in FDR as well as the site of first primary cancer diagnosed in FDR before BCa-2. We also calculated the cumulative incidence of BC from birth to a specific age for the three groups.
RESULTS
RESULTS
The cumulative incidence from birth to age 70 was 10% among women with a family history of BCa-2. The RR of BC with a family history of BCa-2 (RR, 1.68, 95%CI, 1.49 to 1.88) was comparable to that with BCa-1 (1.68, 1.63 to 1.73). The risk was largely consistent irrespective of proband type. The age of onset of BCa-2 in FDR (RR
CONCLUSIONS
CONCLUSIONS
Women with a family history of BCa-2 have a similar overall BC risk as those with a family history of BCa-1. The risk varied according to the site of first primary cancer diagnosed in FDR before BCa-2.
Identifiants
pubmed: 34772394
doi: 10.1186/s12885-021-08925-y
pii: 10.1186/s12885-021-08925-y
pmc: PMC8590230
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1210Informations de copyright
© 2021. The Author(s).
Références
Int J Epidemiol. 2019 Apr 1;48(2):501-511
pubmed: 30668861
Genet Med. 2019 Aug;21(8):1708-1718
pubmed: 30643217
PLoS One. 2013 Dec 27;8(12):e83261
pubmed: 24386167
Mayo Clin Proc. 2020 Jun;95(6):1268-1275
pubmed: 32498779
JCO Precis Oncol. 2020 Aug 19;4:
pubmed: 32954205
Ann Oncol. 2008 Dec;19(12):2084-8
pubmed: 18653701
Sci Rep. 2015 Aug 10;5:12891
pubmed: 26256549
Eur J Cancer. 2010 Mar;46(4):752-7
pubmed: 20022238
Int J Radiat Biol. 2009 Jun;85(6):467-82
pubmed: 19401906
PLoS One. 2018 Jul 26;13(7):e0201097
pubmed: 30048498
Ann Oncol. 2005 Feb;16(2):322-9
pubmed: 15668291
BMC Cancer. 2020 Jan 21;20(1):51
pubmed: 31964352
Acta Oncol. 1997;36(5):465-9
pubmed: 9292741
Int J Cancer. 2017 Dec 1;141(11):2253-2259
pubmed: 28801919
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
J Natl Cancer Inst. 1994 Nov 2;86(21):1600-8
pubmed: 7932824
Med Clin North Am. 2020 Nov;104(6):1007-1021
pubmed: 33099447
JAMA Oncol. 2020 Jan 1;6(1):68-74
pubmed: 31725845
Cancer. 2020 Jun 15;126(12):2837-2848
pubmed: 32154920
Gastroenterology. 2001 Dec;121(6):1348-53
pubmed: 11729114
Int J Cancer. 2014 Apr 15;134(8):1899-906
pubmed: 24590453
Oncol Lett. 2014 Jul;8(1):230-234
pubmed: 24959251
Int J Cancer. 2012 Nov 1;131(9):2085-93
pubmed: 22307919
Cancer Res. 2007 Feb 1;67(3):868-70
pubmed: 17283115
Int J Cancer. 2014 Oct 15;135(8):1756-63
pubmed: 24945890